Can an existing drug calm the itch of rare genetic skin diseases?

NCT ID NCT05649098

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing whether dupilumab, a drug already used for eczema, can reduce severe itching in people with various genetic skin disorders. The trial will enroll 30 participants and last 26 months, including a 16-week treatment period and a longer extension phase. The main goal is to see if itch scores improve significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dupilumab

What this could lead to

If it works, this could point toward a new way to ease severe itching in hard-to-treat genetic skin conditions.

What could go wrong

This is a very early, small pilot study with only 30 people. It may not show clear benefit, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SKIN DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epidermolysis bullosa ichthyosis Pruritus skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact

    Contact Email: •••••@•••••